ArticleBMC bioinformatics2026
ProtSeqGen: a novel deep learning model for protein sequence design.
Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ToxMamba: a novel method for toxic peptide prediction based on the fusion of pretrained embeddings and multi-scale state space models.Briefings in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The protein inverse folding problem, which is the task of designing an amino acid sequence that will fold into a specified backbone structure, represents a fundamental challenge in de novo protein design. Existing computational methods, including deep learning-based approaches, often fail to simultaneously optimize accuracy, stability, efficiency, and generalizability across diverse folds. Here, we present ProtSeqGen, a deep learning model that overcomes these limitations through a multi-stage graph-based framework. ProtSeqGen encodes protein structures as local geometric graphs, explicitly models residue-level interactions using a message-passing neural network, and predicts optimal amino acids with a multi-layer perceptron. When trained on CATH 4.2 dataset and evaluated on standard and challenging benchmarks, ProtSeqGen achieved superior sequence recovery compared to numerous state-of-the-art (SOTA) methods. It also generated accurate, designable sequences for nine topologically diverse proteins, demonstrating remarkable generalization capability. These results establish ProtSeqGen as a robust and scalable solution to the protein inverse folding problem, propelling de novo protein design with high structural precision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.